TOM1: A Drug Target / Disease Biomarker (G10043)

Target Name: TOM1

NCBI ID: G10043

TOM1

TOM1: A Drug Target / Disease Biomarker

TOM1, also known as TOM1-TK, is a protein that is expressed in a variety of tissues, including the brain, pancreas, and muscle. It is a key regulator of the cell cycle, and is involved in the development and maintenance of normal cell structure and function.

Research has identified TOM1 as a potential drug target, due to its involvement in the regulation of cell division and its role in the development of various diseases. In addition, TOM1 has also been identified as a potential biomarker, as its expression has been associated with the development of certain diseases.

One of the key functions of TOM1 is its role in the regulation of the cell cycle. TOM1 is a key regulator of the G1 phase of the cell cycle, which is responsible for cell growth and preparation for cell division. During the G1 phase, TOM1 helps to ensure that the cell has enough chromosomes and organelles for cell division, and also helps to regulate the levels of nuclear proteins.

In addition to its role in the cell cycle, TOM1 is also involved in the regulation of cell division in other ways. For example, TOM1 has been shown to play a role in the regulation of mitosis, the process by which a cell divides. TOM1 has been shown to help ensure that the cell divides correctly, by regulating the levels of the protein metaphosphate.

The association of TOM1 with the development of various diseases has also made it a potential drug target. For example, TOM1 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. In addition, TOM1 has also been associated with the development of certain cancers, such as breast and ovarian cancer.

In addition to its potential as a drug target, TOM1 has also been identified as a potential biomarker. The expression of TOM1 has been shown to be associated with the development of certain diseases, such as neurodegenerative diseases and cancer. This suggests that TOM1 may be a useful biomarker for the diagnosis and treatment of these diseases.

Overall, TOM1 is a protein that is involved in a variety of important cellular processes, including cell division and the regulation of normal cell structure and function. Its potential as a drug target and biomarker make it an attractive target for further research and development.

Protein Name: Target Of Myb1 Membrane Trafficking Protein

Functions: Adapter protein that plays a role in the intracellular membrane trafficking of ubiquitinated proteins, thereby participating in autophagy, ubiquitination-dependent signaling and receptor recycling pathways (PubMed:14563850, PubMed:15047686, PubMed:23023224, PubMed:25588840, PubMed:26320582, PubMed:31371777). Acts as a MYO6/Myosin VI adapter protein that targets MYO6 to endocytic structures (PubMed:23023224). Together with MYO6, required for autophagosomal delivery of endocytic cargo, the maturation of autophagosomes and their fusion with lysosomes (PubMed:23023224). MYO6 links TOM1 with autophagy receptors, such as TAX1BP1; CALCOCO2/NDP52 and OPTN (PubMed:31371777). Binds to polyubiquitinated proteins via its GAT domain (PubMed:14563850). In a complex with TOLLIP, recruits ubiquitin-conjugated proteins onto early endosomes (PubMed:15047686). The Tom1-Tollip complex may regulate endosomal trafficking by linking polyubiquitinated proteins to clathrin (PubMed:14563850, PubMed:15047686). Mediates clathrin recruitment to early endosomes by ZFYVE16 (PubMed:15657082). Modulates binding of TOLLIP to phosphatidylinositol 3-phosphate (PtdIns(3)P) via binding competition; the association with TOLLIP may favor the release of TOLLIP from endosomal membranes, allowing TOLLIP to commit to cargo trafficking (PubMed:26320582). Acts as a phosphatidylinositol 5-phosphate (PtdIns(5)P) effector by binding to PtdIns(5)P, thereby regulating endosomal maturation (PubMed:25588840). PtdIns(5)P-dependent recruitment to signaling endosomes may block endosomal maturation (PubMed:25588840). Also inhibits Toll-like receptor (TLR) signaling and participates in immune receptor recycling (PubMed:15047686, PubMed:26320582)

The "TOM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TOM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets